Q-omics provides the consensus-scored RPL31P59 profile across patient tissues and cancer cell-line models. RPL31P59 expression is associated with patient survival in 10 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, RPL31P59 is differentially expressed in 1, with the highest sampling consensus in STAD. Additionally, RPL31P59 RNA expression shows 5,512 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight LIHC, and STAD as cancer lineages where RPL31P59 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL31P59 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL31P59 survival associations across molecular data types. RPL31P59 RNA expression shows survival associations in the most cancer types (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL31P59 RNA expression–survival associations across cancer types. High RPL31P59 expression shows unfavorable associations in LIHC, KIRC, COAD and KIRP, but favorable associations in HNSC and LAML. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for RPL31P59 RNA expression.
This table summarizes RPL31P59 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in STAD for RNA.
This table ranks reproducible tumor–normal expression differences for RPL31P59. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL31P59 shows higher tumor expression in STAD. The STAD box plot shows higher RPL31P59 RNA expression in tumor versus normal tissue (log2 FC = +0.170, t-test p = .042).
This table shows molecular features associated with RPL31P59 in patient tissues and cancer cell lines. In patient samples, RPL31P59 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
